Success Metrics

Clinical Success Rate
87.5%

Based on 7 completed trials

Completion Rate
88%(7/8)
Active Trials
1(10%)
Results Posted
86%(6 trials)
Terminated
1(10%)

Phase Distribution

Ph phase_1
2
20%
Ph phase_4
1
10%
Ph phase_2
7
70%

Phase Distribution

2

Early Stage

7

Mid Stage

1

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
2(20.0%)
Phase 2Efficacy & side effects
7(70.0%)
Phase 4Post-market surveillance
1(10.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

87.5%

7 of 8 finished

Non-Completion Rate

12.5%

1 ended early

Currently Active

1

trials recruiting

Total Trials

10

all time

Status Distribution
Active(1)
Completed(7)
Terminated(1)
Other(1)

Detailed Status

Completed7
Terminated1
unknown1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
1
Success Rate
87.5%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (20.0%)
Phase 27 (70.0%)
Phase 41 (10.0%)

Trials by Status

completed770%
terminated110%
unknown110%
recruiting110%

Recent Activity

1 active trials
Showing 5 of 10
recruitingphase_2

Eltrombopag for Peripheral Blood Stem Cell Harvest

NCT05961410
completedphase_2

Eltrombopag Olamine in Increasing Platelet Counts in Patients Undergoing Transplant

NCT01927731
completedphase_2

Eltrombopag Olamine in Treating Thrombocytopenia in Patients With Chronic Myeloid Leukemia or Myelofibrosis Receiving Tyrosine Kinase Therapy

NCT01428635
completedphase_2

Phase II Study of Lenalidomide and Eltrombopag in Patients With Symptomatic Anemia

NCT01772420
terminatedphase_1

Eltrombopag Olamine in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia

NCT01550185
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT05961410Phase 2

Eltrombopag for Peripheral Blood Stem Cell Harvest

Recruiting
NCT01927731Phase 2

Eltrombopag Olamine in Increasing Platelet Counts in Patients Undergoing Transplant

Completed
NCT01428635Phase 2

Eltrombopag Olamine in Treating Thrombocytopenia in Patients With Chronic Myeloid Leukemia or Myelofibrosis Receiving Tyrosine Kinase Therapy

Completed
NCT01772420Phase 2

Phase II Study of Lenalidomide and Eltrombopag in Patients With Symptomatic Anemia

Completed
NCT01550185Phase 1

Eltrombopag Olamine in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia

Terminated
NCT02071901Phase 2

Eltrombopag Olamine in Improving Platelet Recovery in Older Patients With Acute Myeloid Leukemia Undergoing Chemotherapy

Unknown
NCT01610180Phase 2

Eltrombopag for the Treatment of Immune ThrombocytoPenia (ITP) Secondary to Chronic Lymphoproliferative Disorders (LPDs)

Completed
NCT00903422Phase 1

Eltrombopag Treatment of Thrombocytopenia in Subjects With Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia After MDS (sAML/MDS)

Completed
NCT01147809Phase 2

Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag

Completed
NCT01098487Phase 4

A Longitudinal 2-year Bone Marrow Study of Eltrombopag in Previously Treated Adults, With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)

Completed

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10